دورية أكاديمية
Stereotactic Body Radiation Therapy With or Without Transarterial Chemoembolization Versus Transarterial Chemoembolization Alone in Early-Stage Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
| العنوان: | Stereotactic Body Radiation Therapy With or Without Transarterial Chemoembolization Versus Transarterial Chemoembolization Alone in Early-Stage Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. |
|---|---|
| المؤلفون: | Dumago MP; Department of Radiation Oncology, Benavides Cancer Institute, University of Santo Tomas Hospital, Manila, Philippines. mark.dumago09@gmail.com., Agas RAF; Department of Radiation Oncology, Benavides Cancer Institute, University of Santo Tomas Hospital, Manila, Philippines.; Stereotactic Ablative Body Radiotherapy Unit, Department of Radiation Oncology, Benavides Cancer Institute, University of Santo Tomas Hospital, Manila, Philippines., Jainar CJE; Department of Radiation Oncology, Benavides Cancer Institute, University of Santo Tomas Hospital, Manila, Philippines., Yap ET; Department of Radiation Oncology, Benavides Cancer Institute, University of Santo Tomas Hospital, Manila, Philippines., Co LBA; Riverside Bacolod Cancer Care Center, Bacolod, Philippines., Ortin TTS; Department of Radiation Oncology, Benavides Cancer Institute, University of Santo Tomas Hospital, Manila, Philippines.; Stereotactic Ablative Body Radiotherapy Unit, Department of Radiation Oncology, Benavides Cancer Institute, University of Santo Tomas Hospital, Manila, Philippines.; Faculty of Medicine and Surgery, University of Santo Tomas, Manila, Philippines. |
| المصدر: | Journal of gastrointestinal cancer [J Gastrointest Cancer] 2023 Dec; Vol. 54 (4), pp. 1058-1070. Date of Electronic Publication: 2023 Jun 12. |
| نوع المنشور: | Meta-Analysis; Systematic Review; Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer Science+Business Media Country of Publication: United States NLM ID: 101479627 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1941-6636 (Electronic) NLM ISO Abbreviation: J Gastrointest Cancer Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2010- : New York : Springer Science+Business Media Original Publication: New York, NY : Humana Press |
| مواضيع طبية MeSH: | Carcinoma, Hepatocellular*/pathology , Liver Neoplasms*/pathology , Radiosurgery*/adverse effects , Chemoembolization, Therapeutic*, Humans ; Retrospective Studies ; Prospective Studies ; Combined Modality Therapy ; Treatment Outcome |
| مستخلص: | Purpose: This study aims to review the current evidence on the utility of stereotactic body radiation therapy (SBRT), with or without transarterial chemoembolization (TACE), for early-stage hepatocellular carcinoma (ESHCC) patients not amenable to standard curative treatment options. Methods: Literature search was conducted using PubMed, ScienceDirect, and Google Scholar. Comparative studies reporting oncologic outcomes were included in the review. Results: Five studies (one phase II randomized controlled trial, one prospective cohort, three retrospective studies) compared SBRT versus TACE. Pooled analysis showed an overall survival (OS) benefit after 3 years (OR 1.65, 95% CI 1.17-2.34, p = 0.005) which persisted in the 5-year data (OR 1.53, 95% CI 1.06-2.22, p = 0.02) in favor of SBRT. RFS benefit with SBRT was also seen at 3 years (OR 2.06, 95% CI 1.03-4.11, p = 0.04) which continued after 5 years (OR 2.35, 95% CI 1.47-3.75, p = 0.0004). Pooled 2-year local control (LC) favored SBRT over TACE (OR 2.96, 95% CI 1.89-4.63, p < 0.00001). Two retrospective studies compared TACE + SBRT versus TACE alone. Pooled analysis showed significantly improved 3-year OS (OR 5.47; 95% CI 2.47-12.11, p < 0.0001) and LC (OR: 21.05; 95% CI 5.01-88.39, p ≤ 0.0001) in favor of the TACE + SBRT group. A phase III study showed significantly improved LC and PFS with SBRT after failed TACE/TAE versus further TACE/TAE. Conclusions: Taking into account the limitations of the included studies, our review suggests significantly improved clinical outcomes in all groups having SBRT as a component of treatment versus TACE alone or further TACE. Larger prospective studies are warranted to further define the role of SBRT and TACE for ESHCC. (© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.) |
| References: | Santopaolo F, Lenci I, Milana M, Manzia T, Baiocchi L. Liver transplantation for hepatocellular carcinoma: Where do we stand? World J Gastroenterol. 2019;25(21):2591–602. https://doi.org/10.3748/wjg.v25.i21.2591 . (PMID: 10.3748/wjg.v25.i21.2591312107126558441) Chen Y, Hsieh P, Lin H, et al. Surgical resection significantly promotes the overall survival of patients with hepatocellular carcinoma: a propensity score matching analysis. BMC Gastroenterol. 2021;21:220. https://doi.org/10.1186/s12876-021-01807-4 . (PMID: 10.1186/s12876-021-01807-4339901848120780) Rhim H, Lim H. Radiofrequency ablation of hepatocellular carcinoma: pros and cons. Gut and liver. 2010;4 Suppl 1(Suppl 1):S113–S118. https://doi.org/10.5009/gnl.2010.4.S1.S113 . Yang J. Detect or not to detect very early stage hepatocellular carcinoma? The western perspective. Clin Mol Hepatol. 2019;25(4):335–43. https://doi.org/10.3350/cmh.2019.0010 . (PMID: 10.3350/cmh.2019.0010309243286933123) Yamakado K, Takaki H, Nakatsuka A, Yamaknaka T, Fujimori M, Hasegawa T, Uraki J. Radiofrequency ablation for hepatocellular carcinoma. Gastrointestinal Intervention. 2014;3(1):35–9. https://doi.org/10.1016/j.gii.2014.04.002 . (PMID: 10.1016/j.gii.2014.04.002) Yun B, Lee H, Min I, Kim S, Park J, Kim D, Ahn S, Kim B. Prognosis of early-stage hepatocellular carcinoma: comparison between trans-arterial chemoembolization and radiofrequency ablation. Cancers. 2020;12(9):2527. https://doi.org/10.3390/cancers12092527 . (PMID: 10.3390/cancers12092527328995847565721) Mazzaferro V, Battiston C, Perrone S, Pulvirenti A, Regalia E, Romito R, Sarli D, Schiavo M, Garbagnati F, Marchianò A, Spreafico C, Camerini T, Mariani L, Miceli R, Andreola S. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg. 2004;240(5):900–9. https://doi.org/10.1097/01.sla.0000143301.56154.95 . (PMID: 10.1097/01.sla.0000143301.56154.95154925741356498) Vivarelli M, Guglielmi A, Ruzzenente A, Cucchetti A, Bellusci R, Cordiano C, Cavallari A. Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver. Ann Surg. 2004;240(1):102–7. https://doi.org/10.1097/01.sla.0000129672.51886.44 . (PMID: 10.1097/01.sla.0000129672.51886.44152136251356381) Ruzzenente A, Guglielmi A, Sandri M, Campagnaro T, Valdegamberi A, Conci S, Bagante F, Turcato G, D’Onofrio M, Iacono C. Surgical resection versus local ablation for HCC on cirrhosis: results from a propensity case-matched study. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract. 2012;16(2):301–11. https://doi.org/10.1007/s11605-011-1745-x . (PMID: 10.1007/s11605-011-1745-x22095524) Kim T, Koh Y, Kim B, Kim M, Lee J, Park B, Park J. Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: a randomized phase III trial. J Hepatol. 2021;74(3):603–612. https://doi.org/10.1016/j.jhep.2020.09.026 . Long Y, Liang Y, Li S, et al. Therapeutic outcome and related predictors of stereotactic body radiotherapy for small liver-confined HCC: a systematic review and meta-analysis of observational studies. Radiat Oncol. 2021;16:68. https://doi.org/10.1186/s13014-021-01761-1 . (PMID: 10.1186/s13014-021-01761-1338325368034166) Chiang C, Chan M, Yeung C, Ho C, Lee F, Lee V, Wong F, Blanck O. Combined stereotactic body radiotherapy and trans-arterial chemoembolization as initial treatment in BCLC stage B-C hepatocellular carcinoma. Kombinierte stereotaktische Körperstamm-Strahlentherapie und transarterielle Chemoembolisation als Erstlinientherapie beim hepatozellulären Karzinom im BCLC-Stadium B–C. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft. 2019;195(3):254–264. https://doi.org/10.1007/s00066-018-1391-2 . Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https://doi.org/10.1136/bmj.n71 . Mohamed M, Katz A, Tejani M, Sharma A, Kashyap R, Noel M, Qiu H, Hezel A, Ramaraju G, Dokus M, Orloff M. Comparison of outcomes between SBRT, yttrium-90 radioembolization, transarterial chemoembolization, and radiofrequency ablation as bridge to transplant for hepatocellular carcinoma. Adv Radiat Oncol. 2015;1(1):35–42. https://doi.org/10.1016/j.adro.2015.12.003 . (PMID: 10.1016/j.adro.2015.12.003287995755506745) Sapisochin G, Barry A, Doherty M, Fischer S, Goldaracena N, Rosales R, Russo M, Beecroft R, Ghanekar A, Bhat M, Brierley J, Greig P, Knox J, Dawson L, Grant D. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis. J Hepatol. 2017;67(1):92–99. https://doi.org/10.1016/j.jhep.2017.02.022 . Su T, Liang P, Zhou Y, Huang Y, Cheng T, Qu S, Chen L, Xiang B, Zhao C, Huang, D, Liang S, Li L. Stereotactic body radiation therapy vs. transarterial chemoembolization in inoperable barcelona clinic liver cancer stage a hepatocellular carcinoma: a retrospective, propensity-matched analysis. Front Oncol. 2020;10:347. https://doi.org/10.3389/fonc.2020.00347 . Wong T, Lee V, Law A, Pang H, Lam K, Lau V, Cui T, Fong A, Lee S, Wong E, Dai J, Chan A, Cheung T, Fung J, Yeung R, Luk M, Leung T, Lo C. Prospective study of stereotactic body radiation therapy for hepatocellular carcinoma on waitlist for liver transplant. Hepatology (Baltimore, Md.). 2021;74(5):2580–2594. https://doi.org/10.1002/hep.31992 . Romero AM, van der Holt B, Willemssen F, de Man R, Heijmen B, Habraken S, Westerveld H, van Delden O, Klumpen H, Tjwa E, Braam P, Jenniskens S, Vanwolleghem T, Weytjens R, d’Archambeau O, de Vos-Geelen J, Buijsen J, van der Leij C, den Toom W, Sprengers D, Ijzermans J, Moelker A. Transarterial chemoembolization with drug-eluting beads vs. stereotactic body radiation therapy for hepatocellular carcinoma: outcomes from a multicenter randomized phase II trial (The TRENDY trial). Int J Radiat Oncol Biol Phys. (20rtog ). https://doi.org/10.1016/j.ijrobp.2023.03.064 . Honda Y, Kimura T, Aikata H, Kobayashi T, Fukuhara T, Masaki K, Nakahara T, Naeshiro N, Ono A, Miyaki D, Nagaoki Y, Kawaoka T, Takaki S, Hiramatsu A, Ishikawa M, Kakizawa H, Kenjo M, Takahashi S, Awai K, Nagata Y, Chayama K. Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma. J Gastroenterol Hepatol. 2013;28(3):530–6. (PMID: 10.1111/jgh.1208723216217) Jun B, Kim S, Kim Y, Cheon G, Han K, Yoo J, Kim Y, Jeong S, Jang J, Lee S, Park S, Kim H. Combined therapy of transarterial chemoembolization and stereotactic body radiation therapy versus transarterial chemoembolization for ≤5cm hepatocellular carcinoma: Propensity score matching analysis. PloS ONE. 2018;13(10):e0206381. https://doi.org/10.1371/journal.pone.0206381 . Comito T, Loi M, Franzese C, Clerici E, Franceschini D, Badalamenti M, Teriaca MA, Rimassa L, Pedicini V, Poretti D, Solbiati LA, Torzilli G, Ceriani R, Lleo A, Aghemo A, Santoro A, Scorsetti M. Stereotactic radiotherapy after incomplete transarterial (Chemo-) embolization (TAE\TACE) versus exclusive TAE or TACE for treatment of inoperable HCC: a phase III trial (NCT02323360). Curr Oncol. 2022;29(11):8802–13. https://doi.org/10.3390/curroncol29110692 . (PMID: 10.3390/curroncol29110692364213459689962) National Health and Medical Research Council: NHRMC additional levels of evidence and grades for recommendation for developers of guidelines. http://www.nhmrc.gov.au/_files_nhmrc/file/pdf . Hasan S, Thai N, Uemura T, Kudithipudi V, Renz P, Abel S, Kirichenko A. Hepatocellular carcinoma with child Pugh-A cirrhosis treated with stereotactic body radiotherapy. World journal of gastrointestinal surgery. 2017;9(12):256–63. https://doi.org/10.4240/wjgs.v9.i12.256 . (PMID: 10.4240/wjgs.v9.i12.256293590315752960) Kimura T, Takeda A, Sanuki N, Ariyoshi K, Yamaguchi T, Imagumbai T, Katoh N, Eriguchi T, Oku Y, Ozawa S, Tsurugai Y, Kokubo M, Shimizu S, Ishikura S. Multicenter prospective study of stereotactic body radiotherapy for previously untreated solitary primary hepatocellular carcinoma: the STRSPH study. Hepatology research : the official journal of the Japan Society of Hepatology. 2021;51(4):461–71. (PMID: 10.1111/hepr.1359533217113) Yoon S, Lim Y, Park M, Kim S, Cho B, Shim J, Kim K, Lee H, Chung Y, Lee Y, Lee S, Lee Y, Park J, Kim J. Stereotactic body radiation therapy as an alternative treatment for small hepatocellular carcinoma. PloS One. 2013;8(11):e79854. https://doi.org/10.1371/journal.pone.0079854 . Yeung R, Beaton L, Rackley T, Weber B, Hamm J, Lee R, Camborde M, Pearson M, Duzenli C, Loewen S, Liu M, Ma R, Schellenberg D. Stereotactic body radiotherapy for small unresectable hepatocellular carcinomas. Clin Oncol (Royal College of Radiologists (Great Britain)). 2019;31(6):365–373. https://doi.org/10.1016/j.clon.2019.01.012 . O’Connor J, Trotter J, Davis G, Dempster J, Klintmalm G, Goldstein R. Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2012;18(8):949–54. https://doi.org/10.1002/lt.23439 . (PMID: 10.1002/lt.2343922467602) Wigg A, Palumbo K, Wigg D. Radiotherapy for hepatocellular carcinoma: Systematic review of radiobiology and modeling projections indicate reconsideration of its use. 2010;25(4):664–71. https://doi.org/10.1111/j.1440-1746.2009.06126.x . (PMID: 10.1111/j.1440-1746.2009.06126.x) Bauer U, Gerum S, Roeder F, Münch S, Combs S, Philipp A, De Toni E, Kirstein M, Vogel A, Mogler C, Haller B, Neumann J, Braren R, Makowski M, Paprottka P, Guba M, Geisler F, Schmid R, Umgelter A, Ehmer U. High rate of complete histopathological response in hepatocellular carcinoma patients after combined transarterial chemoembolization and stereotactic body radiation therapy. World J Gastroenterol. 2021;27(24):3630–42. https://doi.org/10.3748/wjg.v27.i24.3630 . (PMID: 10.3748/wjg.v27.i24.3630342392748240047) Dawson L, Winter K, Knox J, et.al. NRG/RTOG 1112: Randomized phase III study of Sorafenib vs. stereotactic body radiation therapy (SBRT) followed by Sorafenib in hepatocellular carcinoma (HCC) (NCT01730937). Int J Radiat Oncol 2022;114(5):1057. Hall EJ, Giaccia AJ. Radiobiology for the radiologist. Lippincott Williams & Wilkins (LWW). 2018. Wigg A. A randomised controlled trial of standard of care versus radioablation in early stage HCC (The SOCRATES HCC Study). ANZCTR registration number: ACTRN12621001444875p. Retrieved 25 Oct 2021. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=381818&isReview=true . Accessed 5 March 2023. Hung S. Comparing Re-TACE versus SABR for Post-prior-TACE incompletely regressed HCC: a randomized controlled trial (TASABR) (TASABR). ClinicalTrials.gov Identifier: NCT02921139. Retrieved 20 Aug 2021. https://clinicaltrials.gov/ct2/show/NCT02921139 . Accessed 11 April 2023. |
| فهرسة مساهمة: | Keywords: Early-stage hepatocellular carcinoma; Meta-analysis; Stereotactic body radiation therapy; Systematic review; Transarterial chemoembolization |
| تواريخ الأحداث: | Date Created: 20230612 Date Completed: 20231229 Latest Revision: 20231229 |
| رمز التحديث: | 20231229 |
| DOI: | 10.1007/s12029-023-00940-5 |
| PMID: | 37306936 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1941-6636 |
|---|---|
| DOI: | 10.1007/s12029-023-00940-5 |